|
China Resources Pharmaceutical Group is a pharmaceutical and healthcare company engaged in the manufacturing, distribution, and retail of medical products. Its business segments include the industrial production of chemical drugs, traditional Chinese medicine, biological preparations, health products, and medical devices, alongside commercial distribution and retail pharmacy operations. Key subsidiaries include China Resources Pharmaceutical Commercial Group, China Resources Sanjiu, China Resources Shuanghe, China Resources Jiangzhong, Dong-E E-Jiao, and China Resources Boya Biopharmaceutical. The company serves therapeutic areas including cardiovascular, gastrointestinal, pediatric, respiratory, dermatology, blood products, and immunology. Its distribution network covers 28 provinces, autonomous regions, and municipalities in China. The retail segment operates a large pharmacy network, including DTP and dual-channel pharmacies. Notable brands include 999, Dong-E E-Jiao, Shuanghe, Jiangzhong, Boya, Zizhu, Kunzhongyao-1381, Tianshili, and Nanger. Summarised from the company's own disclosures, fiscal year ended Oct 2026 |
Industry Drug Manufacturers - General | Homepage crpharm.com |
| Sector Healthcare | IR page crpharm.com | |
|
Tags
chemical drugs, traditional chinese medicine, biological preparations, medical devices, pharmaceutical distribution, retail pharmacy, blood products, health products, dtp pharmacy, China Resources Pharmaceutical Commercial Group, China Resources Sanjiu, China Resources Shuanghe, China Resources Jiangzhong, Dong-E E-Jiao, China Resources Boya Biopharmaceutical, China Resources Biopharmaceutical, Sichuan Nanger Biotechnology, China Pharmaceutical Research and Development Center, 999, Shuanghe, Jiangzhong, Boya, Zizhu, Kunzhongyao-1381, Tianshili, Nanger
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | HK$ 28.01B |
| Market cap (USD) | $ 3.57B |
| P/E | 6.21 |
| PEG | 1.65 |
| P/BV | 0.20 |
| P/S | 0.09 |
| P/OCF | 1.16 |
| P/FCF | 1.41 |
| Dividend yield | 5.4% |
| Turnover / mcap | 0.06% |
| Returns | |
|---|---|
| ROE | 3.8% |
| ROI | 2.4% |
| ROIC | 2.4% |
| Profit margin | 1.5% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | Yes |
| Revenue up 5y | Yes |
| Earnings growth 3y (net profit CAGR) | 3.8% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | No |
| Buying back stock | — |
| Diluting (TTM) | No |
| Debt/Equity | 45.4% |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | 47.1% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 269.574B | 257.673B | 244.704B | 221.802B | 196.95B | 178.872B | 183.185B | 164.569B | 147.242B | 134.668B | 119.206B |
| Net profit | 4.045B | 3.351B | 3.854B | 3.62B | 3.135B | 2.943B | 2.945B | 3.503B | 2.972B | 2.425B | 2.318B |
| Free cash flow | 16.928B | 14.333B | 12.417B | 7.054B | — | — | — | — | — | — | — |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpAnnouncements and reports published on HKEXnews, newest first, monthly and next-day returns, proxy forms and board-meeting notices included. The link opens the announcement on HKEXnews. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
Company History
Name and ticker changes, and re-registrations under a new regulatory id. When a ticker stopped being used is not recorded, so former tickers are undated.
| Date | Change | Detail |
|---|---|---|
| Dec 31, 2023 | Reporting currency | Its HK reports are in CNY instead of HKD from this period. Earlier figures are shown in CNY, converted at each period end's exchange rate. |
ETFs Holding China Resources Pharmaceutical GP Ltd
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| RFEM | 0.23% | 287,991 | $ 178.103K | Jul 31, 2026 |
| AVEE | 0.13% | 292,500 | $ 167.311K | Nov 16, 2026 |
| DFSE | 0.03% | 256,500 | $ 146.321K | Nov 12, 2026 |
| DFEM | 0.02% | 2,735,500 | $ 1.56M | Nov 12, 2026 |
| DFAE | 0.01% | 1,923,000 | $ 1.097M | Nov 12, 2026 |
| AVEM | 0.01% | 4,682,500 | $ 2.678M | Nov 16, 2026 |
| DFEV | 0.01% | 385,000 | $ 219.624K | Nov 12, 2026 |
| DFAX | 0.01% | 1,424,500 | $ 812.61K | Nov 12, 2026 |






















































